期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

晚期非小细胞肺癌TKIs治疗:关注与思考 被引量：6

TKIs in the Treatment of Advanced Non Small Cell Lung Cancer:attention and thinking
下载PDF
导出
摘要 以表皮生长因子受体(EGFR)为靶点的酪氨酸激酶抑制剂(TKIs)对晚期非小细胞肺癌EGFR突变患者的治疗效果令人瞩目。本文分析总结近年国内外相关研究,指出低剂量TKIs的应用虽有待进一步证实,但优于标准剂量组,并从安全性、改善肿瘤血管结构和功能、与细胞毒化疗的关系三方面探讨大剂量TKIs的应用效果。进一步分析指出大剂量联合小剂量TKIs能够最大程度地防止或延迟耐药的发生,进而控制疾病的进展。从而,为晚期非小细胞肺癌EGFR突变患者的TKIs治疗选择提供参考。 Tyrosine kinase inhibitors targeting （TKIs） in the treatment of advanced non small cell lung cancer patients with EGFR mutation attract people＇s attention. Analysis of related research domestically and abroad, and points out that the application of low dose of TKIs is better than the standard dose group but remains to be further confirmed. This article discussed the application effect of large dose of tyrosine kinase inhibitors from three aspects,including the safety, improve the relationship between tumor vascularstructure and function, and the effect of cytotoxic drugs. At last,it pointed out that the large dose in combination with small dose of TKIs could prevent or delay the occurrence of drug resistance maximally, and the control the progression of the disease. So, it can provide reference for TKIs in the treatment of advanced non small cell lung cancerpatients with EGFR mutations.
作者 王哲海
机构地区 山东省肿瘤医院
出处 《医学与哲学（B）》 2014年第11期11-14,共4页 Medicine & Philosophy(B)
关键词 晚期非小细胞肺癌 表皮生长因子受体 酪氨酸激酶抑制剂 靶向治疗 advanced non-small-cell lung cancer, epidermal growth factor receptor （EGFR）, tyrosine kinase inhibitors （TKIs）, targeted therapy
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Fukuoka M, Yano S, Giaccone G, et al. Multi institutional random- ized phase Ⅱ trial of gefitinib for previously treated patients with advanced non small cell lung cancer (the IDEAL 1 Trial)[J]. J Clin Oncol, 2003,21 (12) : 2237 - 2246.
  • 2Shepherd F A, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non small-cell lung cancer[J]. N Engl J Med, 2005,353(2):123- 132.
  • 3Lynch T J,Bell D W, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non- small-cell lung cancer to gefitinib[J]. N Engl J Med, 2004,350(21 ) : 2129-2139.
  • 4Mok T S,Wu Y L, Thongprasert S, et al. Gefitinib or Carboplatin Paclitaxel in Pulmonary Adenocarcinoma[J]. N Engl J Med, 2009, 361(10) :947-957.
  • 5Satoh H,fnoue A,Kobayashi K, et al. Low Dose Gefitinib Treat- ment for Patients with Advanced Non small Cell Lung Cancer Har- boring Sensitive Epidermal Growth Factor Receptor Mutations[J]. J Thorac Oncol, 2011,6(8) : 1413- 1417.
  • 6Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemother- apy for non small cell lung cancer with mutated EGFR[J]. N Engl J Med,2010,362(25) :2380-2388.
  • 7Yeo W L,Riely G J,Yeap B Y,et al. Erlotinib at a dose of 25 mg daily for non small cell lung cancers with EGFR mutations[J]. J ThoracOncol,2010,5(7):1048- 1053.
  • 8Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacoki- netic, and pharmacodynamic trial of ZD1839, a selective oral epider mal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types[J]. J Clin Oncol,2002,20(21) : 4292-4302.
  • 9Hidalgo M,Siu L L,Nemunaitis J,et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine ki- nase inhibitor, in patients with advanced solid malignancies[J]. J Clin Oncol,2001,19(13) :3267-3279.
  • 10MiltonDT,AzzoliCG,HeelanRT,et al.A Phase Ⅰ/Ⅱ Study of Weekly High Dose Erlotinib in Preveiouly Treated Patienl.s With Nonsmall Cell Lung Cancer[J]. Cancer,2006,107(5) :1034- 1041.

同被引文献66

  • 1Jun ichi S, Yoshihiro S, Tomoko K, et al. Therapeutic Effect of Lin- ac-based Stereotactic Radiotherapy with a Micro-multileaf Collima- tor for the Treatment of Patients with Brain Metastases from Lung Cancer[J].Jpn J Clin Oncol,2010,40(2) : 119-124.
  • 2Fiorino C, Cozzarini C, Rancati T, et al. Modelling the impact of fraction- ation on late urinary toxicity after postprostatectomy radiation therapy [J]. Int J Radiat Oncol Biol Phys, 2014,90(5) : 1250- 1257.
  • 3Englander Z A, Sun J, Laura C, et al. Brain structural connectivity increases concurrent with functional improvement: Evidence from diffusion tensor MRI in children with cerebral palsy during therapy [J].NeuroimageClin,2015 (7) :315- 324.
  • 4Pavy J J,Denekmp J, Lelschefl J, et al. EORTC late Effecte Work- ing Group. Late Effects toxicity scoring: the SOMA scale[J]. Int J Radiat Oncol Biol Phys, 1995,31(5) : 1043- 1047.
  • 5Lizarraga K J, Allen-Auerbach M, Czernin J, et al. 18F-FDOPA PET for Differentiating Recurrent or Progressive Brain Metastatic Tumors from Late or Delayed Radiation Injury After Radiation Treatment[J]. J Nucl Med,2014,55(1) :30-36.
  • 6Kreitzer N, Lyons M S, Hart K, et al. Repeat neuroimaging of mild traumatic brain injured patients with acute traumatic intracranial hemorrhage: clinical outcomes and radiographic features[J]. Acad Emerg Meal,2014,21(10) : 1083- 1091.
  • 7Tang Y M, Rong X M, Hu W H, et al. Effect of edaravone on radia tion-induced brain necrosis in patients with nasopharyngeal carci noma after radiotherapy.-a randomized controlled trial[J]. J Neu rooncol,2014,120(2) : 441 447.
  • 8TYLDESLEY S, BOYD S, CHULZE K, et al. Estimating the need {or radiotherapy {or lung cancer: an evidence-based, epidemiologic approach[J].Int J Radiat OncolBiolPhys,2001,49(4):973 985.
  • 9ONISHI H,SHIRATO H,NAGATA Y,et al. Stereotactic body ra diotherapy (SBRT) for operable stage I non-small-cell lung cancer; can SBRT be comparable to surgery?[J]. Int J Radiat Oncol Biol Phys,2011,81(5) :1352--1358.
  • 10SHIRVANI S M,JIANG J, CHANG J Y, et al. Comparative effec- tiveness of 5 treatment strategies for early stage non-small cell lung cancer in the elderly[J]. Int J Radiat Oncol Biol Phys,2012,84(5) 1060--1070.

引证文献6

二级引证文献45

医学与哲学（B）
2014年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部